SCHEMBL4098362

SCHEMBL4098362

Cc1ccc(-c2ccc(OCCCCl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.55
DRD4 P21917 6/20 0.55
DRD3 P35462 6/20 0.55
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KCNH2 Q12809 2/20 0.47
LSS P48449 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2410855 0.94 DRD2 (0.61) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL11096825 0.89 CYP3A4 (0.52) CYP3A4CYP2D6KCNH2LSSSMN1; SMN2
SCHEMBL6298426 0.87 DRD2 (0.59) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL21185868 0.87 DRD2 (0.57) DRD2DRD4DRD3CYP3A4CYP2D6
SCHEMBL12835092 0.85 DRD2 (0.57) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL20530526 0.85 DRD2 (0.57) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL2489516 0.85 CYP2D6 (0.66) DRD2DRD4DRD3CYP3A4CYP2D6
SCHEMBL5825048 0.85 DRD2 (0.55) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL3805304 0.82 DRD2 (0.68) DRD2DRD4DRD3L3MBTL1KCNH2
SCHEMBL5929468 0.82 DRD2 (0.68) DRD2DRD4DRD3L3MBTL1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874746-B1 DERIVATIVES OF 1-N-AZACYCLOALKYL-3-PHENOXYPROPANE USEFUL FOR THE PREPARATION OF PSYCHOTROPIC MEDICAMENTS BIOPROJET SOC CIV (FR) 2015-11-18 EP disclosed
US-8076329-B2 Histamine H3-receptor ligands and their therapeutic applications BIOPROJET (FR) 2011-12-13 US disclosed
US-20090111808-A1 NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS BIOPROJET (FR) 2009-04-30 US disclosed
EP-1874746-A2 NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS BIOPROJET (FR) 2008-01-09 EP disclosed
WO-2006117609-A2 PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS BIOPROJET (FR) 2006-11-09 WO disclosed
EP-1717234-A1 Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands BIOPROJET (FR) 2006-11-02 EP disclosed
EP-1717235-A2 Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands BIOPROJET (FR) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111808-A1 NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS HRH3, HRH4, HRH1 DRD2 483/4885DRD4 933/4885DRD3 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.